BioIntercept is at the forefront of pulmonary disease research, leveraging cutting-edge technologies to revolutionize the management of lung conditions. Our scientists employ advanced techniques with our proprietary exosome technology to help solve the most challenging problems in respiratory medicine. By delivering targeted therapies that address chronic inflammation and promote tissue repair, we are uncovering crucial insights into disease progression, fibrosis mechanisms, and personalized treatment strategies, paving the way for more effective and regenerative interventions.
Our exosome-based platform shows significant promise in pulmonary indications where inflammation, epithelial injury, and immune dysregulation play central roles: